This $471,675 project grant from the Department of Health and Human Services National Institutes of Health National Cancer Institute Cancer Detection and Diagnosis Research program (CFDA 93.394) will fund research at Oregon Health & Science University to develop a nanoparticle-based blood test to distinguish pancreatic cancer from benign pancreatic disease. The researchers will use high conductance dielectrophoresis technology to simultaneously recover different types of cancer-derived nanoparticles, including exosomes and other extracellular vesicles, from limited patient plasma samples. This will generate new knowledge supporting the clinical development of a nanoparticle biomarker panel for early and late stage pancreatic cancer detection. If validated, such a non-invasive blood test could help stratify patients with pancreatic cysts into high or low probability of having pancreatic ductal adenocarcinoma, avoiding unnecessary invasive procedures for many patients. The grant period is from January 1, 2022 to December 31, 2026.
Generated 1/7/24, 1:55 AM